Apnimed to Participate in Upcoming November Investor Conferences

CAMBRIDGE, Mass. November 6, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...